Introduction
It is now widely recognized that the endothelium is not merely a passive vascular lining but plays an active role in physiological processes such as hemostasis, vasoregulation, and inflammation (1) . Endothelial cells contribute to hemostasis by secreting prostacyclin (PG12)' (2, 3), a powerful inhibitor of platelet function, which is also a vasodilator, and to vasoregulation through prostacyclin and through the phenomenon of endothelium-dependent vasodilation (4), which is induced by several agents including ATP, bradykinin, and thrombin (5, 6) and involves mediator(s) other than PG12 (7) . Endothelial contributions to inflammation include the regulation of leukocyte traffic (neutrophils have a particular affinity for endothelium) and the control of vascular permeability, which is mediated by agents acting either directly on endothelial cells or indirectly, by activating neutrophils, which then secrete constituents (as yet unidentified) that affect the endothelium (8) .
The capacity of activated neutrophils to damage endothelial cells has been noted both in vitro and in vivo, and neutrophil proteases have been implicated in this endothelial cytotoxicity (9) (10) (11) . The endothelial damage recorded in these studies resulted in cell death, whereas neutrophil-dependent increases in vascular permeability involve more subtle (and, presumably, reversible) effects; as potentially lethal stimuli can, at lower concentrations, exert transient, nonlethal effects on endothelial functions (12) , it seemed possible that neutrophil proteases might, under some conditions, reversibly affect endothelial functions involved in vasoregulation. Other proteases are known to exert such effects: Thrombin induces endothelium-dependent vasodilation (13) , and both thrombin and trypsin stimulate prostacyclin production (14) and the selective release of nucleotides from endothelium (15, 16) . Therefore, we set out to determine whether the major neutral proteases of human neutrophils (elastase and cathepsin G) affected PG'2 production and/or nucleotide release from endothelial cells, and whether endothelial responses to stimuli such as ATP, bradykinin, and ionophore A23 187 were altered after exposure to these enzymes.
Possible cytotoxicity was assessed morphologically and biochemically, and the effects of the neutrophil enzymes were compared with those of other neutral proteases. Our results showed a distinctive spectrum of effects of neutrophil elastase on endothelial cell function, different from that of other proteases studied. These effects have implications for the in vivo modulation of inflammation and vasoregulation.
Methods
Materials. Hepes (N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid), trypsin (EC 3.4.21.4 bovine pancreatic, 10,000-13,000 N-abenzoyl-L-arginine ethyl ester U/mg protein), thrombin (human plasma, 3,000 National Institutes of Health (NIH) U/mg protein), a-chymotrypsin (EC 3.4.21.1, type I-S from bovine pancreas), bradykinin triacetate, ATP (disodium salt from equine muscle), N-a-benzoyl-DLarginine p-nitroanilide HC1, pyruvate, and a-nicotinamide adenine dinucleotide (NADH) were all purchased from Sigma Chemical Co., Poole, United Kingdom. Trypsin (1:250) was also obtained from Difco Laboratories, Detroit, MI. Calcium ionophore A23 187, from Calbiochem-Behring, Cambridge, United Kingdom was stored at -200C in dimethyl sulfoxide (stock concentration was 10-2 M).
Neutrophil elastase (EC 3.4.21.37) and cathepsin G (EC 3.4.21.20) were prepared by Drs. J. Saklatvala and A. J. Barrett from human leukocytes obtained by leukophoresis from a patient with chronic myelogenous leukemia ( 17) . Pancreatic elastase was prepared from pig pancreas by Dr. James Travis, University of Georgia, Athens. A specific inhibitor of neutrophil elastase of the chloromethylketone class, CH30-Suc-Ala-Ala-Pro-Val-CH2Cl, was provided by Dr. James C. Powers, Georgia Institute of Technology, Atlanta (18). Furoyl saccharin, a structurally unrelated inhibitor of elastase (19) , was provided by Dr. Morris Zimmerman, Merck Institute, Rahway, NJ.
Endothelial cell columns were perfused either with Dulbecco's modified Eagle's medium (DMEM) to which 20 mM Hepes had been added to maintain the pH at 7.4 or with Krebs' solution of the following composition (in millimolar): NaCl, 119; KCI, 3.1; MgS04, 0.6; NaHCO3, 25; KH2PO4, 1; CaCl2, 1.3; and glucose, I 1.1; pH was maintained at 7.4 by gassing the solution with 95% 02:5% CO2.
Agonists were diluted, at least 100-fold, in the appropriate perfusion medium immediately before use. Unless otherwise stated, cells were exposed to ATP and bradykinin for 2 min, to neutral proteases for 3 min, and to A23187 for 5 min.
Endothelial cell culture. Endothelial cells were isolated from porcine thoracic aorta, essentially as previously described (20) Endothelial cell columns. 0.4-0.5 ml of microcarrier beads covered with endothelial cells (1-2 X 106 cells) was packed into a l-ml plastic syringe plugged with glass wool; the syringe was closed with a rubbertipped plunger through which plastic tubing had been threaded, as previously described (7, 21 The release of lactate dehydrogenase (LDH) from cells in static culture and from columns was assayed according to standard techniques (23) as follows: cells were solubilized in 0.2% Triton X-100 or column fractions were made up to 1.0 ml in 0.2% Triton X-100. 40 gl each of pyruvate and NADH, both at 2.5 mg/ml in PBS, were added and the reaction was followed at room temperature in a double-beam spectrophotometer. The reference cuvette lacked only NADH.
Protease assays. Two assays of protease activity were used, one for trypsinlike activity and another specific for neutrophil elastase activity. The trypsinlike protease assay was a modification of method II of Erlanger et al. (24); it measured the yellow product, p-nitroanilide (E4c0 nm) cleaved from the synthetic substrate benzoyl-D-L-arginine pnitroanilide HCl by trypsin and related seine proteases. 5 M sodium formate, pH 3.0, was used to stop the reaction. The neutrophil elastase assay measured the fluorescent product, 7-amino-4-methylcoumarin (NMec), which is cleaved from the synthetic substrate CH30-Suc-AlaAla-Pro-Val-NMec (provided by Dr. A. J. Barrett). Trypsin, chymotrypsin, and cathepsin G do not cleave this substrate under the conditions of the assay (25) .
Protease assays were used routinely to standardize enzyme activity in all preparations used, to monitor the recovery of enzymes in the column effluent, and to check the effects of inhibitors.
Analysis ofresults. To compare results obtained in different columns, responses were expressed as multiples of the base line value, defined as the ratio of peak response to the mean of five values immediately before exposure to the stimulus. To compare the effects of repeated stimuli on the same column, each net response (peak minus base line) was expressed as a percentage of the net response to the initial stimulus.
Results

Effects ofproteases on endothelial cellfunctions
Stimulation ofprostacyclin production. Trypsin, chymotrypsin, and cathepsin G were all potent stimulators of PG12 production, each with a threshold active concentration <1.0 ,g/ml. Fig. 1 shows the dose-response in one experiment with trypsin (1-100 Ag/ml). Stimulated PG12 production values (mean±SEM) for 1, 10, and 100 ,ug/ml were 3.2±0.6-fold (n = 6), 12.8±2.5-fold (n = 5), and 16.2±4.5-fold (n = 5), respectively, over baseline value. Stimulation of PG12 production was immediate in onset, reached a peak -2 min after addition of the stimulus, and returned towards base line while the stimulus was still present. Patterns of responses to chymotrypsin and cathepsin G were similar to that seen with trypsin: For example, mean responses obtained were 7.4-fold stimulation with 10 gg/ml chymotrypsin and 30-fold stimulation with 100 jg/ml of cathepsin G.
Of the other proteases tested, thrombin and pancreatic elastase stimulated PG12 production with a threshold active concentration of 3-10 ,ug/ml, but maximal stimulation was only 2.8-fold with thrombin (10 NIH U/ml) and 4.6-fold with pancreatic elastase (100 ,g/ml). Neutrophil elastase was also a weak stimulator of PGO2 production, with a threshold active concentration of 10-30 ,ug/ml and little effect even at 100 ,ug/ ml (Fig. 1) .
Stimulation of 3H-purine release. Basal release of purines was 0.15±0.02% min-' of the labeled nucleotide pool (mean±SEM, n = 13, range 0.05-0.29%). Of the proteases studied, neutrophil elastase was the most potent stimulus of 3H-purine release. The lowest effective concentration was -3 ug/ml, and mean responses for 3, 10, and 30 gg/ml were 2.9±0.2-fold (n = 3), 9.8±2.0-fold (n = 5), and 92.4±7.1-fold, respectively, (n = 3) over base-line values. Fig. 2 shows the effect of 1-30 ,g/ml of neutrophil elastase on 3H-purine release in a representative experiment. The response was immediate in onset, peaks occurred -4min after addition of the stimulus and, in contrast to PG12 production, returned toward base line only after removal of the stimulus. Trypsin and pancreatic elastase induced maximal responses of only 3.5±0.5-fold (n = 3) and 1.7-fold over base line, respectively, at 100 gg/ml (Fig. 2) , and thrombin, chymotrypsin, and cathepsin G were also much less effective than neutrophil elastase (e.g., thrombin, at 10 NIH U/ml, stimulated release by 2.4±0.2-fold; n = 3). Thin-layer chromatography of the released 3H-purines showed that neutrophil elastase selectively stimulated the release of nucleotides (ATP, ADP, AMP) rather than nucleosides (inosine, hypoxanthine, adenosine). Basal release of 3H-nucleotides from unstimulated cell columns was <0.05% per min; this rose to a maximum of 0.9% per min after 100 jg/ml trypsin and 6.4% per min after 30 ,ug/ml elastase. These values were obtained by chromatography of samples using a solvent system (26) When cells were challenged a second time with ATP (100 AM) 20 -40 min after the first challenge, the stimulation of PGI2 production was similar to the initial response (96.0±1.7%, n = 5). Since the proteases tested had variable effects on PGI2 production and on purine release, the effects of exposure to these proteases on subsequent PG12 responses to ATP were studied. As shown in Fig. 3 , neutrophil elastase (30 Ag/ml), itself a weak stimulator of PGI2 production but a potent stimulator of 3H-purine release, completely eliminated the PGI2 response to a second challenge with ATP; the second response was 1.3±0.3% of the initial response to ATP (n = 5).
In contrast, PGI2 responses to a second challenge with ATP after exposure to pancreatic elastase, thrombin, and chymotrypsin (all at 30 Ag/ml) averaged 95% of initial ATP responses (n = 3); these three proteases behaved similarly in not affecting PGI2 responses to a second challenge with ATP, despite substantial differences in their potency as direct stimulators of PGI2 production (Fig. 3) . Trypsin, another potent stimulus to PGI2 production, also had no effect on subsequent responses the small amount of purine release in unstimulated samples comprised up to 85% nucleosides. Chromatography under conditions that resolve nucleotides (20) revealed that substantial amounts of ADP and AMP were present in addition to ATP; the proportion varied in different samples. As ATP is by far the most abundant nucleotide within endothelial cells (20) , the presence of the AMP and ADP suggests that released ATP may be metabolized by endothelial ectonucleotidases, as found in previous studies (15) .
Endothelial cell cytotoxicity. Incubation with 30 ,ug/ml neutrophil elastase for 5 min at 370C had no effect on cell morphology, or on trypan blue exclusion (-99% in control and treated cultures). Some uptake of trypan blue was noted after 15 min incubation with 3G Ag/ml neutrophil elastase (though not with 3 or 10 gg/ml), as well as detachment of some cells from the culture vessel. Basal release of LDH from columns was 0.78±1.16%/min (n = 11) of total column activity and varied up to 2.5-fold during individual experiments. There was no increase in LDH release during a 3-min infusion of neutrophil elastase at concentrations up to 30 gg/ml (mean, 0.67% min), nor over the 20-min period after the elastase infusions. This indicates that under these conditions elastase neither induced leakage of LDH nor detached cells from the beads. Infusion of 100 UM ATP, either before or after elastase, had no effect on LDH release (0.36%/min), and the other proteases tested were also without effect on LDH release.
Effects ofproteases on endothelial cell responses to vasoactive agents A TP-induced PGI2 production. ATP (100 AM) stimulated PGI2 production by 18.2±3.2-fold over basal production (n = 11). Prostacyclin production by endothelial cells on microcarrier beads in response to ATP before and after exposure to neutrophil elastase, pancreatic elastase, thrombin, or chymotrypsin. Enzymes (30 ug/ml), cell columns, and aliquots for assay were prepared as described in Fig. 2 legend. (Fig. 4) . ATP also stimulates the production of PGE2 by endothelial cells (27) , and in some samples the effect of elastase on ATP-induced PGE2 production was determined; PGE2 was inhibited in parallel with PG'2. In separate experiments, we found that the ability of ATP to release [3H]arachidonate from prelabeled endothelial cells (22) was also inhibited after exposure to elastase. The duration of the inhibition of ATP-stimulated prostaglandin production by neutrophil elastase was studied by repeated additions of 100 MM ATP at varying intervals after exposure to elastase (30 MAg/ml). PG12 production in response to ATP was abolished 20-30 min after elastase but increased progressively from -40 min onwards, returning to normal after -2 h.
Effects of neutrophil elastase on stimulation ofPGI2
production by bradykinin and ionophore A23187
To determine whether neutrophil elastase inhibited P012 production induced by agents other than ATP, responses to bradykinin and ionophore A23187 were studied. The PG12 response to 3 X 10-8 M bradykinin was reduced by '90%, 20 min after exposure to elastase (30 Mg/ml). Desensitization was seen with repeated exposure to bradykinin alone (second responses were about half of initial responses), which made elastase effects difficult to quantify, but in all experiments responses after elastase, when compared with responses to bradykinin alone, were consistently reduced although not abolished. The calcium ionophore A23187 was a potent stimulus of PG12 production but endothelial cells do not respond to successive challenges. Therefore, to test the effects ofgranulocyte elastase on responses to A23187, two cell columns prepared from the same microcarrier culture, only one of which was exposed to neutrophil elastase, were both exposed to A23187 at identical times from the onset of perfusion. Cells not exposed to elastase showed a 96.4±19.6-fold increase in PG12 production to A23187 (10 gM, 5 min);:columns exposed to elastase (30 gg/nml, 3 min exposure 40 min before A23187) showed a 91.2±13.3-fold increase over basal PG12 production (n = 4). Thus, endothelial PG12 production in response to A23187 is unaffected by prior exposure to neutrophil elastase.
Effects ofneutrophil elastase after enzyme inhibition
To determine the role of the catalytic site in the effects of neotrophil elastase on endothelial cells, concentrations of elastase known to abolish subsequent PG12 responses to ATP were incubated for 1 h with fivefold molar excess concentrations of the specific chloromethylketone inhibitor of neutrophil elastase, CH3O-Suc-Ala-Ala-Pro-Val-CH2Cl (12) . This abolished elastase activity against a specific substrate (see Methods). As shown in Fig. 5 , neutrophil elastase (30 Mg/ml) previously incubated with inhibitor had virtually the same effect on PG12 responses to ATP as the enzyme alone; similar results were obtained with furoyl saccharin, a structurally unrelated elastase inhibitor (19) . Furthermore, neutrophil elastase-inhibitor mixtures were as powerful stimuli of 3H-purine release as were comparable concentrations of neutrophil elastase alone. The inhibitor alone had no effect on 3H-purine release or on responses to ATP. Heat treatment of the elastase preparation (100I C for 5 min) did not block its effect on endothelial cells, but preincubation with serum inhibited its effect.
The resistance of this elastase effect to enzyme inactivation contrasts with stimulation of endothelial PG12 production by trypsin (which we found was abolished by heat inactivation or soybean trypsin inhibitor) or by thrombin (which is abolished by treatment with diisopropylfluorophosphonate; see reference 16).
Discussion
The results of our present study demonstrate that neutrophil elastase, although a weak stimulator of PGI2 production compared with some other neutral proteases, inhibited PG12 production in response to other stimuli, especially ATP. Furthermore, in contrast to the other neutral proteases studied, neutrophil elastase was a powerful stimulator of adenine nucleotide release. Responses to neutrophil elastase were immediate, of brief duration, and were not associated with endothelial cell injury as measured by LDH Stimulation of endothelial PG12 production by thrombin, trypsin, and chymotrypsin (14) was confirmed, and the kinetics of responses explored. Cathepsin G, another powerful stimulant, has not been tested previously. This enzyme is one of the two most abundant neutral proteases in human neutrophils (the other being elastase) and is also released when neutrophils degranulate. The concentrations of 6-oxo-PGFIa measured in column eluates after stimulation with cathepsin G indicate that similar responses in vivo would have profound biological effects: peak concentrations were 5-30 ng/ml, and PG12 at concentrations around 0.1 ng/ml inhibits platelet aggregation (2).
Neutrophil elastase ,g/ml) stimulated purine release, whereas other proteases tested at comparable concentrations had little or no effect. Previous reports of trypsin-induced nucleotide release used 1 mg/ml, the concentration routinely used to subculture cells (15) ; the present study showed that trypsin (100 jsg/ml) stimulated nucleotide release (as distinct from total 3H-purine release) by sixfold. This can be compared with >200-fold stimulation of nucleotide release by 30 gg/ml neutrophil elastase.
Neutrophil elastase also inhibited ATP-stimulated endothelial cell PG12 production; the mechanisms responsible are not yet known, but the possibilities are: (a) nonspecific cytotoxic effects; (b) receptor desensitization through release of ATP; (c) a direct effect of elastase on the receptor for ATP, either by proteolysis or via nonenzymic binding to the receptor. Relevant arguments include: (a) elastase did not have conventional cytotoxic effects under the conditions of our experiments, and did not disrupt the prostaglandin synthetic machinery (stimulation of PGI2 production by ionophore A23187 was unaffected); (b) stimulation of PG12 production by repeated additions of ATP (100 ,M) showed no desensitization; (c) inhibition of the catalytic site with a specific inhibitor did not block the effects of neutrophil elastase on endothelial cells. Thus, neutrophil elastase probably exerts its effects on endothelial cells by nonenzymic binding to the cell surface, as has been described for mononuclear cells (28) . The concept that proteins can have multiple domains with biological activity is not unique to elastase: Several such examples are known, and some of these activities (like the ability of elastase to release purines from endothelial cells) are resistant to heat treatment; for example, the routine procedure for purification of plateletderived growth factor involves boiling the preparation, and heating granulocyte cationic proteins increases their bactericidal and cytotoxic activity while destroying their proteolytic activity (29, 30) .
The question remains as to which domain(s) on the elastase molecule might be involved in functional interactions with the endothelial surface. Recent studies in our laboratory (Needham, L. A., and J. L. Gordon, unpublished results) have shown that cationic (but not uncharged) polymers such as polylysine, polyarginine, and polyornithine induce 3H-purine release from endothelial cells, and that their effectiveness increases with molecular size. This suggests that the elastase domain responsible for stimulating endothelial cells contains an assembly of basic amino acids. The possibility that the effects observed with elastase were caused by some contaminant introduced during preparation of the enzyme seems unlikely, because three different enzyme preparations were tested, in addition to two unpurified preparations of neutrophil granule extracts, which also stimulated purine release.
There is evidence that the effects of neutrophil granule proteins on (11) , and endothelial injury in vivo has been observed after neutrophil activation and degranulation but not after granulocyte-endothelial cell contact alone (9, 10) . It should be noted that although previous studies in vitro (like our own experiments) used endothelial cells cultured from large vessels, most neutrophil-endothelial interactions in vivo take place in the microcirculation; whether endothelial cells from these different vascular sites respond similarly to neutrophil products remains to be determined. Previous studies of neutrophil-endothelial interactions in vitro usually determined cell death as the end point of injury, whereas the present study deals mainly with more subtle and reversible effects of neutrophil elastase on endothelial functions; however, we also noted that increasing the concentrations and/or exposure time resulted in cytotoxic effects, consistent with the concept that a potentially damaging stimulus can reversibly affect cell functions at lower concentrations than those that are cytotoxic (12) . The concentrations of neutrophil elastase to which endothelial cells might be exposed in vivo are difficult to predict accurately but, on the basis of the extent of neutrophil-endothelial interaction that has been observed (8, 10, 31) and the content of elastase in human neutrophils (32), we can calculate that degranulation of neutrophils in the microcirculation could produce local concentrations of elastase in the range of 10-100 jg/ml, with concentrations in the microenvironment at the endothelial surface transiently even higher. The effects of this released elastase on endothelium would depend largely on the efficiency with which plasma inhibitors acted: We found that incubation with serum or plasma blocked the effects of elastase on endothelial cells but it is known that where there is intimate cell-substrate contact (as occurs in neutrophil-endothelial adhesion; see references 8, 10, 31) plasma inhibitors are, at least temporarily, ineffective (33).
The reversible effects of neutrophil elastase on endothelial cells may be important in the context of vasoregulation, because ATP is a potent vasoactive agent (34) that stimulates the release of vasodilator prostaglandins (including PG12) from vascular beds (35-36) and from endothelial cells in culture (reference 27 and Fig. 3) , and also induces endotheliumdependent vasodilation (5, 6) in some blood vessels (13) by an unknown mechanism not involving prostaglandins (5, 7) . Thus, the ability of neutrophil elastase to release nucleotides from endothelial cells could be expected to result in vasodilation, were it not for the fact that elastase temporarily blocks ATPinduced PG12 production. Whether elastase also blocks ATPinduced endothelium-dependent relaxation has not yet been established, and therefore it is not clear at present if exposure of endothelium to elastase in vivo would compromise all ATPinduced vasodilation, or only in those vessels where the effect of PGI2 predominated. This topic merits investigation, because loss of endothelium-dependent vasodilation results in exaggerated vasoconstrictor responses (37) , which might contribute to the paradoxical vasospasm seen in some conditions of peripheral vascular disease, such as those associated with Raynaud's phenomenon (38) .
